Boston Scientific device outperforms warfarin in atrial fibrillation study

05/10/2013 | MassDevice.com (Boston)

Boston Scientific's Watchman device proved more effective and safer in treating patients with atrial fibrillation than the anti-coagulant drug warfarin, according to a 707-participant study. The study showed Watchman was superior to warfarin "for the combined endpoint of all stroke, cardiovascular or unexplained death and systemic embolism," the company said in a release.

View Full Article in:

MassDevice.com (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Director of Operations - GBS
Mayo Clinic
Rochester, MN
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Senior Vice President, Clinical Affairs & Strategic Partnerships
America's Health Insurance Plans (AHIP)
Washington, DC